BioCentury
ARTICLE | Clinical News

AbbVie's upadacitinib meets in second Phase III for RA

September 12, 2017 12:07 AM UTC

AbbVie Inc. (NYSE: ABBV) said both doses of oral upadacitinib (ABT-494) met the two primary endpoints in the Phase III SELECT-BEYOND trial to treat moderate to severe rheumatoid arthritis. Upadacitinib is an oral Janus kinase-1 (JAK-1) inhibitor.

On the first primary endpoint, a significantly greater proportion of patients who received once-daily 15 and 30 mg doses of upadacitinib achieved a 20% improvement in the American College of Rheumatology criteria (ACR20) at week 12 vs. placebo (65% and 56%, respectively, vs. 28%, p<0.001 for both). On the second primary endpoint, a significantly greater proportion of patients receiving low- and high-dose upadacitinib achieved low disease activity, defined as a disease activity score using 28 joint counts calculated using C-reactive protein (DAS28-CRP) score of less than or equal to 3.2 points, at week 12 vs. placebo (43% and 42%, respectively, vs. 14%, p<0.001 for both). ...